Monthly summary - April

Rates and geopolitics versus earnings! Following five months of positive equity market returns, April turned out to be a somewhat harder month to navigate. The hopes for fast upcoming cuts from central banks were again dashed by stickier inflation, especially in the US, leading to yet another delay in when it could be expected. At the beginning of 2024 the expectation was half dozen cuts, this expectation has been reduced to one or two cuts, or maybe none at all.

Weaker than expected growth

Towards the end of the month, GDP- and PCE-figures were released. These showed weaker than expected growth combined with higher inflation; the worst of both worlds for investors, already apprehensive of ‘higher for longer’ interest rates, who were thus even more concerned over the implications of a slowing economy.

Earnings season in full swing

With the earnings season in full swing, outcomes were generally positive as far as profits, revenues and outlooks were concerned and, on average, better than expected. However, investors’ responses were mixed, to say the least. For example, Tesla, which had fallen more than 40 percent between the beginning of the year and the middle of April, delivered weak earnings, but hopes for a new model range a few years down the line made the stock jump by more than 10 percent, on top of which a visit by Elon Musk to China added another 15 percent. On the other hand, Meta (Facebook) delivered better than expected earnings but said that its investments in Artificial Intelligence would increase, and the stock fell by double digits. On balance, however, Q1 reports were positively received.

Situation in the Middle East deteriorated

The situation in the Middle East deteriorated further with a tit-for-tat aggression between Israel and Iran. After the Iranian embassy in Damascus, Syria, was attacked, presumably by Israel, Iran retaliated by launching around 300 missiles and drones aimed at Israel. Almost all were shot down by the Israeli defense system, aided by the US, the UK and France. Israel responded with a new attack, this time against airbases inside Iran. However, it soon became evident that neither side wanted an escalation of the conflict, and worries about a full-fledged war in the region subsided. Also, negotiations between Israel and Hamas continued with, it was thought, a possible ceasefire expected before too long. The oil price initially rose strongly as supply issues due to the conflict became evident, but later fell back somewhat as the hostilities seemed to calm down.

The US passed a new financial package

The other geopolitical hot spot, Ukraine and the Russian aggression, came into renewed focus as the plea for further aid was finally met when the US eventually passed a new financial package after months of deliberations and political mongering. Otherwise, the Ukrainians, outnumbered both in terms of personnel and munitions, could have faced even more difficulties from the Russian onslaught.

Risk willingness abated in April

After a strong first quarter, risk willingness abated in April, which became the first month with negative returns since October of last year. Again, large swings in FX, not least the strengthening of the US dollar, implied that the outcome varied depending on investors´ base currency. With the exception of energy and utilities, all global sectors fell in April, with information technology and consumer discretionary falling most. Europe outperformed the US and Japan, while Hong Kong posted the best regional return.

 

OUTLOOK

After five months of growth, April experienced a setback. In the healthcare sector, a half-percent rise in the US 10-year Treasury bond provided particularly strong headwinds for small caps and the smaller biotech companies. The stock markets had a negative month. The fear was that interest rate cuts would be postponed for longer and that growth in the US would start to decline as a result of the high interest rate situation. The concept of stagflation was even raised by some of the most pessimistic forecasters.

Likely a pause

We are more optimistic than that. The decline in inflation has certainly stopped, possibly only temporarily, but nothing we see points to rising inflation. Housing costs are still the largest component of the consumer price index, but these should gradually come down, albeit with a certain delay, based, among other things, on seasonal factors which should now become more favorable. The American labor market is cooling somewhat and wage inflation will probably slow down as a result. According to our assessment, the inflation outlook should look better already in a month or so.

Opportunity to buy quality companies

The reporting season has started well. We look forward to what we believe will be both continued good reports and a more balanced US economy. The European economy also appears to have bottomed out. A minor slump in the stock market can be seen as an opportunity to buy quality companies. Unfortunately, the smaller companies have to wait for an improved environment and for inflation to drop again. Fundamentally, many healthcare companies are doing well, with few exceptions.

Andra nyheter från oss

All

Direkt

Finwire

Uncategorized

Rhenman & Partners

Monthly comment (Apr 25): Healthcare sector impacted by political uncertainty

Monthly summary – March 2025: a volatile month, again impacted by the macro-economic and political backdrop

Rhenman Healthcare Equity L/S minskade 13,61 procent i mars – volatilt för hälsovårdssektorn

Monthly summary – February 2025: Sentiment turned sour in February

Rhenman Healthcare Equity L/S sjönk 4,52 procent i februari – politisk osäkerhet pressade marknaden

Rhenman & Partners strengthens its Operations Team

Rhenman & Partners förstärker sitt Operationsteam

Monthly comment – January 2025: All sectors except technology closing in positive territory

Rhenman Healthcare Equity L/S ökade 8,41 procent i januari – stark rotation mot hälsovård

Monthly comment – December 2024

Rhenman Healthcare Equity L/S minskade 10,48 procent i december – tungt avslut på 2024

Monthly summary – November 2024: Once the election results were in, focus shifted torwards likely economic implications

Rhenman Healthcare Equity L/S ökade 1,67 procent i november – volatilt efter valet i USA

How is the healthcare sector affected by the US election results?

Hur påverkas en av världens mest reglerade sektorer av valutgången i USA?

Rhenman Healthcare Equity L/S minskade 2,00 procent i oktober – fokus på rapportperiod och USA-val

October 2024 summary – Initital focus on the earnings season switched to focus on election outcomes

Rhenman Healthcare Equity L/S föll 3,53 procent i september – positiv långsiktig utsikt trots volatil marknad

Monthly summary – September 2024

Rhenman & Partners strengthens its Investor Relations team further

Rhenman & Partners förstärker sitt Investor Relations-team ytterligare

Monthly summary – August 2024

Rhenman Healthcare Equity L/S ökade 3,35 procent i augusti – optimistisk syn på andra halvåret

Rhenman & Partners förstärker investeringsteamet – ytterligare en portföljförvaltare inom biopharma

Rhenman & Partners strengthens investment team – hires additional biopharma PM

Rhenman Healthcare Equity L/S ökade 5,26 procent i juli – tydlig sektorrotation

Monthly update – July 2024

Rhenman Healthcare Equity L/S ökade 1,42 procent i juni – stark månad för aktiemarknaden

Monthly summary – June 2024

Rhenman & Partners celebrates 15 years

Rhenman Healthcare Equity L/S föll 1,29 procent i maj – ser positivt på andra halvåret

Monthly summary – May 2024

Rhenman Healthcare Equity L/S minskade 2,57 procent i april – svag utveckling för de flesta delsektorer

Rhenman Healthcare Equity L/S ökade 5,86 procent i mars – starka bidrag från medicinteknik

Monthly summary – March 2024

Rhenman & Partners strengthens its investor relations team

Rhenman & Partners förstärker Investor Relations

Rhenman Healthcare Equity L/S ökade 4,45 procent i februari – stark månad för bioteknik

Monthly summary – February 2024

Rhenman Healthcare Equity ökade 6,17 procent i januari – Shockwave och Eli Lilly bidrog positivt

Monthly summary – January 2024

Monthly summary – December 2023

Rhenman Healthcare Equity L/S ökade 5,43 procent i december – Cytokinetics bidrog positivt till utvecklingen

Monthly summary – November 2023

Monthly update – November 2023

Rhenman Healthcare Equity ökade 3,58 procent i november – Immunogen bidrog positivt

Monthly summary – October

Rhenman Healthcare Equity minskade 3,03 procent i oktober – två uppköp under månaden

The complex reality of investing in Biopharma

Rhenman Healthcare Equity minskade 6,07 procent i september – Immunovant steg kraftigt efter goda resultat

Monthly summary – September

Rhenman Healthcare Equity ökade 2,91 procent i augusti – Eli Lilly och Novo Nordisk i blickfånget

MONTHLY SUMMARY – AUGUST 2023

Rhenman Healthcare Equity minskade 4,01 procent i juli – Apellis Pharmaceuticals tyngde utvecklingen

Rhenman Healthcare Equity L/S ökade 2,65 procent i juni – ökar allokeringen mot tryggare bolag

Monthly summary – June 2023

Susanna Urdmark lämnar Rhenman & Partners

Susanna Urdmark to leave Rhenman & Partners

Susanna Urdmark lämnar Rhenman & Partners

Rhenman Healthcare Equity ökade 3,24 procent i maj – Immunogen bidrog positivt till utvecklingen

Dan Hoflund ny styrelseledamot för Rhenman & Partners Asset Management

Rhenman Healthcare Equity L/S ökade 3,83 procent i april – Tenet Health utvecklades starkt

Monthly summary – April 2023

Rhenman Healthcare Equity L/S minskade 1,02 procent i mars – Novo Nordisk aktiekurs fortsätter stiga

Monthly summary – March 2023

Lars Wedenborn ny styrelseledamot för Rhenman & Partners Asset Management

Lars Wedenborn – ny styrelseledamot Rhenman & Partners Asset Management

Rhenman Healthcare Equity L/S minskade 4,42 procent i februari – rekyl på aktiemarknaderna under februari

Monthly summary – February 2023

Rhenman Healthcare Equity ökade 3,75 procent i januari – Revance Therapeutics och Tenet Healthcare bidrog positivt (uppdatering)

Rhenman Healthcare Equity ökade 3,75 procent i januari – Revance Therapeutics och Tenet Healthcare bidrog positivt

Monthly summary – January 2023

Rhenman Healthcare Equity minskade 4,76 procent i december – Horizon Therapeutics främsta bidragsgivare

Monthly summary – December 2022

Rhenman & Partners strengthens its investment team with a biopharma analyst

Rhenman & Partners förstärker sitt investeringsteam med biopharmananlytiker

Rhenman Healthcare Equity L/S ökade 2,51 procent i november – Abiomed och Horizon Health bidrog positivt

Summary – November 2022

Rhenman Healthcare Equity L/S: +5,7% i oktober, flera faktorer pekar på hyfsad vinter men makrorisker ska ej underskattas – förvaltare

Summary – October 2022

Rhenman Healthcare Equity L/S ökade 5,68 procent i oktober – lyfter fram potentiell presidentcykeleffekt

Rhenman Healthcare Equity L/S: -1,5% i september, investmentbanker sänkte Jazz Pharmaceuticals och Vitrolife (R)

Rhenman Healthcare Equity L/S minskade 1,5 procent i september – Revance Therapeutics och Regeneron Pharmaceuticals främsta bidragsgivare

Teresa Isele ny vd för Rhenman & Partners Asset Management

Teresa Isele ny VD för Rhenman & Partners Asset Management AB

Teresa Isele to be the new CEO of Rhenman & Partners Asset Management AB

Rhenman Healthcare Equity L/S: +1,7% i augusti, förvaltare positiva till amerikansk läkemedelsreform

Rhenman Healthcare Equity L/S ökade 1,70 procent i augusti – biotekniksektorn gynnade utvecklingen

Rhenman Healthcare Equity L/S RC1 SEK: +5,4% i juli, ser på uppgångarna med försiktighet

Rhenman Healthcare Equity L/S ökade 5,39 procent i juli – fortsatt försiktig inställning

Rhenman Healthcare Equity L/S: +4,5% i juni, ser inte läge att öka aktieexponering trots viss ljusning.

Rhenman Healthcare Equity L/S ökade 4,50 procent i juni – stark återhämtning från små- och medelstora bioteknikbolag

Rhenman Healthcare Equity L/S minskade 3,19 procent i maj – stora läkemedelsbolag bidrog positivt

RHENMAN HEALTHCARE EQUITY L/S: -3,2% I MAJ, BUD PÅ BIOHAVEN

Rhenman & Partners fortsätter att expandera – sök rollen som biopharma-analytiker

Rhenman & Partners winner of Refinitiv Lipper Fund Awards Nordics

Rhenman & Partners vinnare av internationellt fondpris

Lediga tjänster inom Investor Relations

Rhenman Healthcare Equity L/S: -4,9% i april, tyngdpunkt på stora bolag för tillfället

Rhenman Healthcare Equity L/S minskade 4,93 procent i april – läkemedelsbolag minst påverkade av ökad global osäkerhet

EN